BCG: Binah Capital Group's First Profitable Year Masks Real Dilution Concerns

Key Data (as of April 1, 2026, 10:05 AM ET):

• Price: $2.62 (+30.34%)
• Volume: 23.89M (massive spike)
• Float: ~12-14M shares (estimated)
• Market Cap: $33.37M
• 52-Week Range: $1.36 - $3.44

BCG exploded 30% Tuesday morning after reporting fourth-quarter earnings that showed the wealth management company’s first profitable year since going public. The stock surged 59.20% in after-hours trading Monday following strong fourth-quarter results, then continued climbing through the regular session.

But while management celebrates turning a $4.6 million net loss in 2024 into $2.3 million profit for 2025, there’s more to this story than the press release suggests.

The Numbers Behind the Victory Dance

Full-year revenue hit $187.1 million, up 11% from 2024, driven mainly by higher commissions and advisory fees. Q4 revenue grew 13.2% year-over-year to $50.5 million, while assets under management grew 11% to $29.9 billion.

The profitability turnaround is real. GAAP diluted earnings per share improved from a loss of $0.07 per share in Q4 2024 to $0.01 profit. EBITDA increased to $5.4 million from $1.9 million, while Adjusted EBITDA was $6.5 million versus $6.3 million.

Those aren’t terrible numbers for a $33 million company. BCG operates through 10 entities — four broker-dealers, three registered investment advisors, and three insurance entities — essentially consolidating wealth management businesses under one roof.

What the Earnings Call Didn’t Emphasize

Here’s where things get interesting. The company held $10.7 million cash against $17.7 million in long-term debt as of December 31. That’s not catastrophic leverage, but it’s not exactly fortress-like either for a company trying to grow through acquisitions.

More concerning is the share structure. BCG has 16.60 million shares outstanding, with the count increasing 1.45% in one year. The company also has 1,626,000 Series A Convertible Preferred shares outstanding as of December 31, 2025, up from 1,555,000 the previous year.

Those preferred shares represent a ticking dilution bomb that most retail traders probably aren’t calculating into their valuation models.

The Volume Pattern Tells a Story

Tuesday’s 23.89 million share volume is massive for a stock that typically trades under 100,000 shares daily. The stock has a pattern of responding well to improving earnings, with prior results showing an average next-day move of 6.44%, including a 21.4% jump after Q3 2025.

The stock is trading below its 200-day moving average of $2.09, which means this earnings spike pushed it back above longer-term resistance. That’s constructive, but technical analysis shows a sell signal for both the current rating and 1-week outlook.

Benzinga’s Edge Stock Rankings indicate BCG has negative price trends across all timeframes — a reminder that momentum can reverse quickly on small-caps.

The Real Question for Traders

BCG’s business model isn’t broken. Recent announcements show advisory teams selecting its PKS Investments subsidiary as their broker-dealer, highlighting Binah’s role in providing scale and advisor-focused resources. The asset management industry benefits from market growth, and BCG’s 11% AUM expansion proves they’re capturing some of that.

But at $2.62, you’re paying roughly 14x trailing EBITDA for a company with meaningful debt, dilution risk, and dependency on market conditions for fee growth. The earnings beat was real, but so are the structural headwinds.

Key levels to watch: $2.80 represents the session high and would signal continuation above yesterday’s after-hours peak. Support sits around $2.20, roughly where the stock traded before earnings. Below $2.00 puts you back under that 200-day moving average and suggests the earnings euphoria was short-lived.

The convertible preferred shares remain the wild card that could pressure the stock if holders start converting on strength.

This analysis was prepared on April 1, 2026, at 10:05 AM ET during regular trading hours. Past performance doesn’t guarantee future results.